title: Colorectal cancers in patients with the (9A/6A) polymorphism of TGFBR1 exhibit lesser inter-(simple sequence repeat) PCR genomic instability and present clinically at greater age.
abstract: TGFbeta is involved in the response to DNA damage and signaling the cell cycle checkpoint response, in large part achieved by modulating the activity of the ATM kinase. We have investigated if the presence of a common polymorphism in the TGFbeta receptor TGFBR1 might impact genomic instability in human colorectal cancer. In order to obtain statistically significant numbers of patients with the lesser polymorphism, 177 colorectal cancer patients were genotyped for either the major form of the TGFBR1 receptor gene, homozygous for an internal segment of 9 alanines (9A/9A), or the lesser form, heterozygous for the polymorphism containing 6 alanines (9A/6A). Intrachromosomal genomic instability in the tumors was then quantified by the robust inter-(simple sequence repeat) PCR method. Tumors from all 26 patients heterozygous with the (9A/6A) polymorphism in TGFBR1 exhibited significantly lower genomic instability than from a randomly selected set [the first identified] of 37 patients with the (9A/9A) polymorphism (p=0.0002, Mann-Whitney). The median age of onset for the (9A/6A) patients was 70 years, compared with a median age of onset of 63 years for the patients carrying the (9A/9A) form (p=0.031, Mann-Whitney). These results are consistent with the model wherein genomic instability facilitates tumor progression, with lesser instability associated with later disease presentation. Clinically, our findings may be developed into improved screening guidelines with respect to the age at which colonoscopy is initiated in carriers of the TGFBR1*6A allele.
authors.affiliation: Department of Cancer Biology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
authors.forename: Smitha S
authors.initials: SS
authors.lastname: Dutt
authors.forename: Neng
authors.initials: N
authors.lastname: Chen
authors.forename: Huferesh K
authors.initials: HK
authors.lastname: Darbary
authors.forename: Helen
authors.initials: H
authors.lastname: Swede
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Petrelli
authors.forename: Daniel L
authors.initials: DL
authors.lastname: Stoler
authors.forename: Garth R
authors.initials: GR
authors.lastname: Anderson
mesh_terms: D000328:Adult; D017668:Age of Onset; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D001483:Base Sequence; D015179:Colorectal Neoplasms / Q000235:genetics*; D004249:DNA Damage; D017931:DNA Primers / Q000235:genetics; D004273:DNA, Neoplasm / Q000235:genetics; D005260:Female; D042822:Genomic Instability; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D008297:Male; D008875:Middle Aged; D018598:Minisatellite Repeats; D011110:Polymorphism, Genetic; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*; D000077293:Receptor, Transforming Growth Factor-beta Type I; D018125:Receptors, Transforming Growth Factor beta / Q000235:genetics*; D015398:Signal Transduction / Q000235:genetics
chemical_list: D017931:DNA Primers; D004273:DNA, Neoplasm; D018125:Receptors, Transforming Growth Factor beta; D017346:Protein Serine-Threonine Kinases; D000077293:Receptor, Transforming Growth Factor-beta Type I; C000625841:TGFBR1 protein, human
references.citation: J Thorac Oncol. 2007 Jul;2(7):657-9
references.pmid: 17607123
references.citation: Cancer Res. 2001 Nov 15;61(22):8274-83
references.pmid: 11719460
references.citation: Science. 2005 Oct 7;310(5745):68-71
references.pmid: 16210527
references.citation: Science. 2006 Oct 13;314(5797):268-74
references.pmid: 16959974
references.citation: Oncol Res. 2005;15(4):233-8
references.pmid: 17822283
references.citation: Oncogene. 2005 Jul 14;24(30):4861-6
references.pmid: 15897900
references.citation: J Clin Oncol. 2005 May 1;23(13):3074-8
references.pmid: 15860866
references.citation: Cell. 2000 Jan 7;100(1):57-70
references.pmid: 10647931
references.citation: Cancer Genet Cytogenet. 2006 Jul 15;168(2):98-104
references.pmid: 16843098
references.citation: Br J Cancer. 2007 Oct 22;97(8):1175-9
references.pmid: 17848956
references.citation: Genes Chromosomes Cancer. 1997 Jan;18(1):19-29
references.pmid: 8993977
references.citation: Gastroenterology. 2003 Feb;124(2):544-60
references.pmid: 12557158
references.citation: Science. 1998 May 15;280(5366):1086-8
references.pmid: 9582123
references.citation: Cancer Res. 1999 Nov 15;59(22):5678-82
references.pmid: 10582683
references.citation: Science. 1995 Jun 2;268(5215):1336-8
references.pmid: 7761852
references.citation: JAMA. 2005 Oct 5;294(13):1634-46
references.pmid: 16204663
references.citation: Nat Genet. 2001 Oct;29(2):117-29
references.pmid: 11586292
references.citation: Cancer Res. 2006 Nov 15;66(22):10861-9
references.pmid: 17090522
references.citation: Mutat Res. 2004 Dec 21;568(2):283-92
references.pmid: 15542115
references.citation: Bioessays. 2001 Nov;23(11):1037-46
references.pmid: 11746220
references.citation: Int J Cancer. 1999 Jul 2;82(1):43-51
references.pmid: 10360819
references.citation: Cancer Res. 2001 Nov 15;61(22):8351-2
references.pmid: 11719470
references.citation: Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18238-42
references.pmid: 17108085
references.citation: Cancer Res. 1998 Jul 1;58(13):2727-32
references.pmid: 9661882
references.citation: Nat Rev Cancer. 2003 Mar;3(3):155-68
references.pmid: 12612651
references.citation: Ann Surg Oncol. 2002 Nov;9(9):901-6
references.pmid: 12417513
references.citation: Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15121-6
references.pmid: 10611348
references.citation: J Clin Oncol. 2005 Oct 20;23(30):7743-4; author reply 7744-6
references.pmid: 16234535
references.citation: Clin Cancer Res. 2007 Jun 15;13(12):3748-52
references.pmid: 17575241